Disease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis
Valizadeh A, Fattahi M, Sadeghi M, Torbati M, Sahraian M, Azimi A. Disease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis. CNS Neuroscience & Therapeutics 2022, 28: 648-657. PMID: 35218155, PMCID: PMC8981477, DOI: 10.1111/cns.13815.Peer-Reviewed Original ResearchMeSH KeywordsAdultHumansImmunosuppressive AgentsMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingConceptsDisease-modifying therapiesCertainty of evidenceVolumes of T1Hypointense lesionsMultiple sclerosis patientsRisk of biasRoB 2 toolT1-hypointense lesionsRandom-effects modelEffects of FDANumber of lesionsAdult patientsSclerosis patientsMultiple sclerosisComparator groupPrognostic markerObjective markersSystematic reviewLesionsMean differenceMean volumePatientsRelevant studiesHypointenseTherapy